Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $23.00 by Analysts at Oppenheimer

Keros Therapeutics (NASDAQ:KROS - Free Report) had its price objective lowered by Oppenheimer from $63.00 to $23.00 in a report published on Thursday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

KROS has been the subject of several other reports. Wedbush restated an "outperform" rating and set a $84.00 target price on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Finally, Guggenheim lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, December 16th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Keros Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

Shares of KROS traded up $0.34 during mid-day trading on Thursday, reaching $10.86. The company's stock had a trading volume of 2,986,409 shares, compared to its average volume of 2,606,141. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $73.00. The stock has a market cap of $439.91 million, a PE ratio of -2.08 and a beta of 1.43. The company's fifty day moving average price is $37.51 and its two-hundred day moving average price is $47.36.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period in the previous year, the company earned ($1.33) earnings per share. The firm's revenue was up 4750.0% compared to the same quarter last year. Research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KROS. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after purchasing an additional 577,220 shares during the period. Alkeon Capital Management LLC raised its stake in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after buying an additional 298,694 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock worth $24,493,000 after buying an additional 223,155 shares during the period. Assenagon Asset Management S.A. boosted its position in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock valued at $12,990,000 after acquiring an additional 199,245 shares in the last quarter. Finally, FMR LLC boosted its position in Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after acquiring an additional 179,374 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.